Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.